Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca...
https://pubmed.ncbi.nlm.nih.gov/30415602/Actively Recruiting
Led by Shanghai Zhongshan Hospital · Updated on 2025-05-14
5600
Participants Needed
13
Research Sites
N/A
Total Duration
This research evaluates the effects and safety of implementing a diabetic guideline algorithm by primary care physicians in a community setting. It focuses on elderly patients aged 65 and older with type 2 diabetes who have high or very high cardiovascular risk and complications such as chronic kidney disease or cardiovascular disease. The study aims to see if the guideline-based intervention can reduce major cardiovascular events and improve cardiovascular and renal outcomes over time. The trial is a cluster-randomized controlled study with two groups one receiving intensive guideline algorithm implementation prioritizing drugs like SGLT2 inhibitors or GLP-1 receptor agonists for high-risk patients, targeting specific blood sugar, blood pressure, and cholesterol goals and the other receiving conventional guideline-based care managed by local physicians with education support. The intervention targets include HbA1C under 7%, blood pressure below 13080 mmHg, and LDL cholesterol below certain thresholds depending on risk level. The study duration is four years, with Phase 1 assessing control of risk factors at 18 months and Phase 2 evaluating cardiovascular and kidney outcomes at three years. Participants will undergo assessments to monitor blood sugar control, blood pressure, cholesterol levels, kidney function, cardiovascular events, and other health markers such as heart function, retinopathy, cognitive function, and frailty over the study period. Data collection includes measuring primary outcomes like combined cardiovascular events and hospitalization for heart failure, as well as secondary outcomes including changes in glycemic control, kidney disease progression, and body weight. Safety and adherence to treatment guidelines will be tracked throughout. The study involves regular follow-up to evaluate the impact of guideline implementation on health outcomes in elderly diabetics with high cardiovascular risk.
CONDITIONS
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community
X
Xiaoying Li, MD
X
Xiaomu Li, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shanghai Zhongshan Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants receive guideline algorithm-based interventions implemented by primary care physicians to manage diabetes and cardiovascular risk factors, including prioritization of specific anti-diabetic drugs and comprehensive control of blood sugar, blood pressure, and lipids.
Regular visits scheduled by primary care physicians during treatment
Duration - Up to 1 year after treatment
Participants are monitored for cardiovascular and renal outcomes and safety after receiving the guideline algorithm intervention.
Visits as needed for outcome assessments up to 4 years total study duration
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Stephen D Wiviott, Itamar Raz, Marc P Bonaca...
https://pubmed.ncbi.nlm.nih.gov/30415602/Francesco Cosentino, Peter J Grant, Victor Aboyans...
https://pubmed.ncbi.nlm.nih.gov/31497854/Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink...
https://pubmed.ncbi.nlm.nih.gov/34233928/Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais...
https://pubmed.ncbi.nlm.nih.gov/31189511/Steven P Marso, Stephen C Bain, Agostino Consoli...
https://pubmed.ncbi.nlm.nih.gov/27633186/Deepak L Bhatt, Michael Szarek, P Gabriel Steg...
https://pubmed.ncbi.nlm.nih.gov/33200892/Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter...
https://pubmed.ncbi.nlm.nih.gov/32970396/Vlado Perkovic, Meg J Jardine, Bruce Neal...
https://pubmed.ncbi.nlm.nih.gov/30990260/Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen...
https://pubmed.ncbi.nlm.nih.gov/27295427/Shanghai Zhongshan Hospital
Lead Sponsor